Business Context and Reporting Period
This Form 8-K Current Report covers events occurring on December 30, 2015, and January 6, 2016, for Omeros Corporation. The filing primarily details the entry into a new Loan and Security Agreement and an At-the-Market Issuance Sales Agreement, alongside the termination of a prior debt agreement and operational changes to its sales force.
Key Financial Metrics and Agreements
- New Debt Facility: Omeros borrowed an initial principal amount of $50.0 million from Oxford Finance LLC and East West Bank.
- Debt Capacity: The company may borrow up to an additional $20.0 million in two tranches of $10.0 million each by June 30, 2017, contingent on minimum net revenue from the product Omidria.
- Interest Rate: Fixed annual rate of 9.25%.
- Repayment Terms: Interest-only payments monthly through July 1, 2017. Principal and interest payments begin August 1, 2017, with a maturity date of January 1, 2020.
- Debt Extinguishment Loss: The company anticipates recognizing a loss of approximately $1.3 million in Q4 2015 financial statements.
- Equity Facility: Established an At-the-Market Issuance Sales Agreement allowing for the sale of up to $100.0 million of common stock, with a 1.7% commission to the agent.
- Liquidity Impact: Cash debt service obligation is reduced by $11.4 million during the interest-only period compared to the prior agreement.
Material Changes Versus Prior Period
- Debt Restructuring: Omeros used approximately $27.5 million of the new loan proceeds to repay all amounts owed under its prior Loan and Security Agreement (dated March 5, 2014), terminating that agreement and releasing associated security interests.
- Use of Proceeds: Approximately $22.3 million of the initial loan proceeds (after costs) is designated for general corporate purposes and working capital.
- Operational Shift: Effective January 1, 2016, the dedicated contract field sales force for Omidria was converted from inVentiv Commercial Services, LLC to Omeros employees, though inVentiv will continue providing sales support.
Guidance, Risks, and Covenants
- Covenants: The Loan Agreement requires Omeros to achieve minimum net revenue amounts from Omidria through 2018 and maintain at least $10.0 million in cash and cash equivalents.
- Restrictions: The agreement limits the company's ability to incur additional indebtedness, grant liens, merge, dispose of assets, pay dividends, or repurchase stock without lender approval.
- Security Interest: Omeros granted a security interest in substantially all assets, excluding intellectual property (though proceeds from IP are included).
- Events of Default: Includes non-payment, covenant breaches, material adverse changes, and insolvency. A default interest rate of 5.00% above the applicable rate applies during an event of default.
- Unusual Items: A final payment fee of 7.50% of the initial principal ($3.75 million) plus 5.25% of any additional borrowings is due at maturity or upon prepayment.
Investor Verification Checklist
- Verify the actual net revenue generated from Omidria to ensure compliance with the minimum revenue covenants required to access the additional $20.0 million tranche.
- Monitor the company's cash and cash equivalents balance to ensure it remains above the $10.0 million covenant threshold.
- Review the Q4 2015 financial statements for the recorded $1.3 million loss on debt extinguishment.
- Assess the impact of the 9.25% interest rate and the 7.50% final payment fee on future cash flow projections.
- Check for any future equity dilution resulting from the utilization of the $100.0 million At-the-Market Issuance Sales Agreement.